Pancreatic foamy gland adenocarcinoma

Summary

Pancreatic foamy gland adenocarcinoma (MONDO:0004287) is a disease. A subtype of pancreatic ductal adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic foamy gland adenocarcinoma
Mondo ID	MONDO:0004287
DOID	DOID:7577
NCIT	C37256
UMLS	C1335303
MedGen	235450
GARD	0027674
Is cancer (heuristic)	no

Also known as: pancreatic foamy gland adenocarcinoma

Disease family

This is a subtype of pancreatic ductal adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › tubular adenocarcinoma › pancreatic ductal adenocarcinoma › pancreatic foamy gland adenocarcinoma

Related subtypes (4): pancreatic signet ring cell adenocarcinoma, mixed ductal-endocrine carcinoma of pancreas, colloid carcinoma of the pancreas, undifferentiated pancreatic carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.